Insider Buying: Surrozen (NASDAQ:SRZN) Director Purchases 15,100 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 15,100 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was acquired at an average price of $19.89 per share, with a total value of $300,339.00. Following the purchase, the director owned 989,893 shares in the company, valued at $19,688,971.77. This represents a 1.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Tim Kutzkey also recently made the following trade(s):

• On Friday, December 5th, Tim Kutzkey purchased 30,884 shares of Surrozen stock. The shares were acquired at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The stock was acquired at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The shares were acquired at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Shares of NASDAQ:SRZN traded down $0.91 during midday trading on Thursday, reaching $19.06. 14,409 shares of the company’s stock traded hands, compared to its average volume of 76,400. The company has a fifty day simple moving average of $17.88 and a two-hundred day simple moving average of $13.47. Surrozen, Inc. has a 1 year low of $5.90 and a 1 year high of $24.94. The company has a market cap of $163.34 million, a P/E ratio of -0.85 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. As a group, research analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Analyst Ratings Changes

SRZN has been the topic of several research analyst reports. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Surrozen presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Trading of Surrozen

Several hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC grew its holdings in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares in the last quarter. Armistice Capital LLC purchased a new position in Surrozen in the second quarter valued at $536,000. Woodline Partners LP purchased a new position in Surrozen in the third quarter valued at $621,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Surrozen in the third quarter valued at $889,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.